• 1
    van Bergen J, Thompson A, Haasnoot GW, et al. KIR-ligand mismatches are associated with reduced long-term graft survival in HLA-compatible kidney transplantation. Am J Transplant 2011; 11: 19591964.
  • 2
    Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. Immunology 2010; 129: 819.
  • 3
    Parham P, Norman PJ, Abi-Rached L, Guethlein LA. Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules. Philos Trans R Soc Lond B Biol Sci 2012; 367: 800811.
  • 4
    Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: Lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011; 132: 315325.
  • 5
    Cheent K, Khakoo SI. Natural killer cells: integrating diversity with function. Immunology 2009; 126: 449457.
  • 6
    Gardiner CM. Killer cell immunoglobulin-like receptors on NK cells: The how, where and why. Int J Immunogenet 2008; 35: 18.
  • 7
    Hanvesakul R, Kubal C, Moore J, et al. KIR and HLA-C interactions promote differential dendritic cell maturation and is a major determinant of graft failure following kidney transplantation. PLoS One 2011; 6: e23631.
  • 8
    Kreijveld E, van der Meer A, Tijssen HJ, Hilbrands LB, Joosten I. KIR gene and KIR ligand analysis to predict graft rejection after renal transplantation. Transplantation 2007; 84: 10451051.
  • 9
    Kunert K, Seiler M, Mashreghi MF, et al. KIR/HLA ligand incompatibility in kidney transplantation. Transplantation 2007; 84: 15271533.
  • 10
    Nowak I, Majorczyk E, Wisniewski A, et al. Does the KIR2DS5 gene protect from some human diseases? PLoS One 2010; 5: e12381.
  • 11
    Stern M, Elsasser H, Honger G, Steiger J, Schaub S, Hess C. The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am J Transplant 2008; 8: 13121317.
  • 12
    Tran TH, Mytilineos J, Scherer S, Laux G, Middleton D, Opelz G. Analysis of KIR ligand incompatibility in human renal transplantation. Transplantation 2005; 80: 11211123.
  • 13
    Vampa ML, Norman PJ, Burnapp L, Vaughan RW, Sacks SH, Wong W. Natural killer-cell activity after human renal transplantation in relation to killer immunoglobulin-like receptors and human leukocyte antigen mismatch. Transplantation 2003; 76: 12201228.
  • 14
    Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
  • 15
    Mytilineos J, Scherer S, Dunckley H, et al. DNA HLA-DR typing results of 4000 kidney transplants. Transplantation 1993; 55: 778781.
  • 16
    Scherer S, Mytilineos J, Forssmann U, et al. Analysis of rare HLA-DRB1-DQB1 haplotypes in kidney donors and recipients. Transplant Proc 1995; 27: 684685.
  • 17
    Ashouri E, Ghaderi A, Reed EF, Rajalingam R. A novel duplex SSP-PCR typing method for KIR gene profiling. Tissue Antigens 2009; 74: 6267.
  • 18
    Maxwell LD, Wallace A, Middleton D, Curran MD. A common KIR2DS4 deletion variant in the human that predicts a soluble KIR molecule analogous to the KIR1D molecule observed in the rhesus monkey. Tissue Antigens 2002; 60: 254258.
  • 19
    Kikuchi-Maki A, Yusa S, Catina TL, Campbell KS. KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J Immunol 2003; 171: 34153425.
  • 20
    Murphy WJ, Parham P, Miller JS. NK cells—from bench to clinic. Biol Blood Marrow Transplant 2012; 18(Suppl): S2S7.
  • 21
    Trundley AE, Hiby SE, Chang C, et al. Molecular characterization of KIR3DL3. Immunogenetics 2006; 57: 904916.
  • 22
    Norman PJ, Carrington CV, Byng M, et al. Natural killer cell immunoglobulin-like receptor (KIR) locus profiles in African and South Asian populations. Genes Immun 2002; 3: 8695.
  • 23
    Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113: 726732.
  • 24
    Kroger N, Zabelina T, Berger J, et al. Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 2011; 25: 16571661.
  • 25
    Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 20972100.
  • 26
    Rajalingam R, Gebel HM. KIR-HLA mismatching in human renal allograft transplantation: Emergence of a new concept. Am J Transplant 2011; 11: 17711772.
  • 27
    Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008; 180: 39693979.